Intrinsic value of Cardiovascular Systems - CSII

Previous Close

$24.47

  Intrinsic Value

$0.89

stock screener

  Rating & Target

str. sell

-96%

Previous close

$24.47

 
Intrinsic value

$0.89

 
Up/down potential

-96%

 
Rating

str. sell

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of CSII stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2017), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.8

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2017(a)
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  15.17
  10.40
  9.86
  9.37
  8.94
  8.54
  8.19
  7.87
  7.58
  7.32
  7.09
  6.88
  6.69
  6.53
  6.37
  6.24
  6.11
  6.00
  5.90
  5.81
  5.73
  5.66
  5.59
  5.53
  5.48
  5.43
  5.39
  5.35
  5.31
  5.28
  5.25
Revenue, $m
  205
  226
  249
  272
  296
  322
  348
  375
  404
  433
  464
  496
  529
  564
  600
  637
  676
  716
  759
  803
  849
  897
  947
  999
  1,054
  1,111
  1,171
  1,234
  1,299
  1,368
  1,440
Variable operating expenses, $m
 
  297
  326
  357
  389
  422
  456
  492
  530
  568
  609
  651
  694
  740
  787
  836
  887
  940
  995
  1,053
  1,114
  1,177
  1,242
  1,311
  1,383
  1,458
  1,537
  1,619
  1,705
  1,795
  1,889
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  206
  297
  326
  357
  389
  422
  456
  492
  530
  568
  609
  651
  694
  740
  787
  836
  887
  940
  995
  1,053
  1,114
  1,177
  1,242
  1,311
  1,383
  1,458
  1,537
  1,619
  1,705
  1,795
  1,889
Operating income, $m
  -2
  -71
  -78
  -85
  -92
  -100
  -109
  -117
  -126
  -135
  -145
  -155
  -165
  -176
  -187
  -199
  -211
  -224
  -237
  -250
  -265
  -280
  -295
  -312
  -329
  -347
  -365
  -385
  -405
  -427
  -449
EBITDA, $m
  2
  -66
  -73
  -80
  -87
  -94
  -102
  -110
  -118
  -127
  -136
  -145
  -155
  -165
  -175
  -186
  -198
  -210
  -222
  -235
  -248
  -262
  -277
  -292
  -308
  -325
  -343
  -361
  -380
  -400
  -421
Interest expense (income), $m
  1
  2
  3
  4
  4
  5
  6
  7
  8
  9
  10
  11
  12
  13
  15
  16
  17
  19
  20
  21
  23
  25
  26
  28
  30
  32
  34
  36
  38
  41
  43
Earnings before tax, $m
  -2
  -73
  -80
  -88
  -97
  -106
  -115
  -124
  -134
  -144
  -155
  -166
  -177
  -189
  -202
  -215
  -228
  -242
  -257
  -272
  -288
  -304
  -322
  -340
  -359
  -379
  -399
  -421
  -444
  -467
  -492
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -2
  -73
  -80
  -88
  -97
  -106
  -115
  -124
  -134
  -144
  -155
  -166
  -177
  -189
  -202
  -215
  -228
  -242
  -257
  -272
  -288
  -304
  -322
  -340
  -359
  -379
  -399
  -421
  -444
  -467
  -492

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  109
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  194
  94
  103
  113
  123
  133
  144
  156
  167
  180
  192
  206
  219
  234
  249
  264
  280
  297
  315
  333
  352
  372
  393
  414
  437
  461
  486
  512
  539
  567
  597
Adjusted assets (=assets-cash), $m
  85
  94
  103
  113
  123
  133
  144
  156
  167
  180
  192
  206
  219
  234
  249
  264
  280
  297
  315
  333
  352
  372
  393
  414
  437
  461
  486
  512
  539
  567
  597
Revenue / Adjusted assets
  2.412
  2.404
  2.417
  2.407
  2.407
  2.421
  2.417
  2.404
  2.419
  2.406
  2.417
  2.408
  2.416
  2.410
  2.410
  2.413
  2.414
  2.411
  2.410
  2.411
  2.412
  2.411
  2.410
  2.413
  2.412
  2.410
  2.409
  2.410
  2.410
  2.413
  2.412
Average production assets, $m
  37
  40
  44
  48
  53
  57
  62
  67
  72
  77
  83
  88
  94
  100
  107
  113
  120
  128
  135
  143
  151
  160
  169
  178
  188
  198
  208
  220
  231
  244
  256
Working capital, $m
  118
  10
  11
  12
  13
  14
  15
  17
  18
  19
  20
  22
  23
  25
  26
  28
  30
  32
  33
  35
  37
  39
  42
  44
  46
  49
  52
  54
  57
  60
  63
Total debt, $m
  21
  29
  37
  46
  55
  64
  74
  84
  95
  106
  117
  129
  141
  154
  167
  181
  196
  211
  226
  243
  260
  277
  296
  315
  336
  357
  379
  402
  427
  452
  479
Total liabilities, $m
  76
  84
  92
  101
  110
  119
  129
  139
  150
  161
  172
  184
  196
  209
  222
  236
  251
  266
  281
  298
  315
  332
  351
  370
  391
  412
  434
  457
  482
  507
  534
Total equity, $m
  118
  10
  11
  12
  13
  14
  15
  16
  18
  19
  20
  22
  23
  25
  26
  28
  30
  31
  33
  35
  37
  39
  42
  44
  46
  49
  51
  54
  57
  60
  63
Total liabilities and equity, $m
  194
  94
  103
  113
  123
  133
  144
  155
  168
  180
  192
  206
  219
  234
  248
  264
  281
  297
  314
  333
  352
  371
  393
  414
  437
  461
  485
  511
  539
  567
  597
Debt-to-equity ratio
  0.178
  2.900
  3.400
  3.830
  4.210
  4.540
  4.840
  5.100
  5.330
  5.550
  5.740
  5.910
  6.070
  6.210
  6.350
  6.470
  6.580
  6.690
  6.780
  6.880
  6.960
  7.040
  7.110
  7.180
  7.250
  7.310
  7.370
  7.420
  7.470
  7.520
  7.560
Adjusted equity ratio
  0.106
  0.106
  0.106
  0.106
  0.106
  0.106
  0.106
  0.106
  0.106
  0.106
  0.106
  0.106
  0.106
  0.106
  0.106
  0.106
  0.106
  0.106
  0.106
  0.106
  0.106
  0.106
  0.106
  0.106
  0.106
  0.106
  0.106
  0.106
  0.106
  0.106
  0.106

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -2
  -73
  -80
  -88
  -97
  -106
  -115
  -124
  -134
  -144
  -155
  -166
  -177
  -189
  -202
  -215
  -228
  -242
  -257
  -272
  -288
  -304
  -322
  -340
  -359
  -379
  -399
  -421
  -444
  -467
  -492
Depreciation, amort., depletion, $m
  4
  4
  5
  5
  6
  6
  7
  7
  8
  8
  9
  10
  10
  11
  12
  12
  13
  14
  15
  16
  17
  18
  19
  20
  21
  22
  23
  24
  25
  27
  28
Funds from operations, $m
  25
  -68
  -75
  -83
  -91
  -99
  -108
  -117
  -126
  -136
  -146
  -156
  -167
  -178
  -190
  -202
  -215
  -228
  -242
  -256
  -271
  -287
  -303
  -320
  -338
  -357
  -376
  -397
  -418
  -441
  -464
Change in working capital, $m
  5
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  3
Cash from operations, $m
  20
  -69
  -76
  -84
  -92
  -100
  -109
  -118
  -127
  -137
  -147
  -158
  -168
  -180
  -192
  -204
  -217
  -230
  -244
  -258
  -273
  -289
  -306
  -323
  -341
  -359
  -379
  -400
  -421
  -444
  -467
Maintenance CAPEX, $m
  0
  -4
  -4
  -5
  -5
  -6
  -6
  -7
  -7
  -8
  -8
  -9
  -10
  -10
  -11
  -12
  -12
  -13
  -14
  -15
  -16
  -17
  -18
  -19
  -20
  -21
  -22
  -23
  -24
  -25
  -27
New CAPEX, $m
  -2
  -4
  -4
  -4
  -4
  -5
  -5
  -5
  -5
  -5
  -5
  -6
  -6
  -6
  -6
  -7
  -7
  -7
  -8
  -8
  -8
  -9
  -9
  -9
  -10
  -10
  -11
  -11
  -12
  -12
  -13
Cash from investing activities, $m
  -2
  -8
  -8
  -9
  -9
  -11
  -11
  -12
  -12
  -13
  -13
  -15
  -16
  -16
  -17
  -19
  -19
  -20
  -22
  -23
  -24
  -26
  -27
  -28
  -30
  -31
  -33
  -34
  -36
  -37
  -40
Free cash flow, $m
  18
  -77
  -85
  -93
  -102
  -111
  -120
  -130
  -140
  -150
  -161
  -172
  -184
  -196
  -209
  -222
  -236
  -250
  -265
  -281
  -297
  -314
  -332
  -351
  -370
  -390
  -411
  -434
  -457
  -481
  -507
Issuance/(repayment) of debt, $m
  21
  8
  8
  9
  9
  9
  10
  10
  11
  11
  11
  12
  12
  13
  13
  14
  14
  15
  16
  16
  17
  18
  19
  19
  20
  21
  22
  23
  24
  25
  27
Issuance/(repurchase) of shares, $m
  9
  74
  81
  89
  98
  107
  116
  125
  135
  145
  156
  167
  179
  191
  203
  216
  230
  244
  259
  274
  290
  307
  324
  342
  361
  381
  402
  424
  447
  470
  495
Cash from financing (excl. dividends), $m  
  29
  82
  89
  98
  107
  116
  126
  135
  146
  156
  167
  179
  191
  204
  216
  230
  244
  259
  275
  290
  307
  325
  343
  361
  381
  402
  424
  447
  471
  495
  522
Total cash flow (excl. dividends), $m
  47
  5
  5
  5
  5
  5
  6
  6
  6
  6
  7
  7
  7
  7
  8
  8
  8
  9
  9
  9
  10
  10
  11
  11
  12
  12
  13
  13
  14
  15
  15
Retained Cash Flow (-), $m
  -17
  -74
  -81
  -89
  -98
  -107
  -116
  -125
  -135
  -145
  -156
  -167
  -179
  -191
  -203
  -216
  -230
  -244
  -259
  -274
  -290
  -307
  -324
  -342
  -361
  -381
  -402
  -424
  -447
  -470
  -495
Prev. year cash balance distribution, $m
 
  109
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  40
  -77
  -84
  -93
  -101
  -110
  -120
  -129
  -139
  -150
  -160
  -172
  -183
  -196
  -208
  -222
  -235
  -250
  -265
  -280
  -296
  -313
  -331
  -350
  -369
  -389
  -410
  -433
  -456
  -480
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  38
  -70
  -73
  -76
  -78
  -80
  -81
  -81
  -80
  -78
  -76
  -73
  -70
  -66
  -61
  -56
  -51
  -46
  -41
  -36
  -31
  -26
  -22
  -18
  -14
  -11
  -9
  -7
  -5
  -4
Current shareholders' claim on cash, %
  100
  45.6
  20.8
  9.5
  4.3
  2.0
  0.9
  0.4
  0.2
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee. Its products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral. The Company's coronary arterial disease (CAD) product, Diamondback 360 Coronary OAS (Coronary OAS), is marketed as a treatment for severely calcified coronary arteries.

FINANCIAL RATIOS  of  Cardiovascular Systems (CSII)

Valuation Ratios
P/E Ratio -401.9
Price to Sales 3.9
Price to Book 6.8
Price to Tangible Book
Price to Cash Flow 40.2
Price to Free Cash Flow 44.7
Growth Rates
Sales Growth Rate 15.2%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -60%
Cap. Spend. - 3 Yr. Gr. Rate -31.2%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 17.8%
Total Debt to Equity 17.8%
Interest Coverage -1
Management Effectiveness
Return On Assets -0.6%
Ret/ On Assets - 3 Yr. Avg. -18.4%
Return On Total Capital -1.7%
Ret/ On T. Cap. - 3 Yr. Avg. -23.6%
Return On Equity -1.8%
Return On Equity - 3 Yr. Avg. -23.7%
Asset Turnover 1.2
Profitability Ratios
Gross Margin 80.5%
Gross Margin - 3 Yr. Avg. 79.6%
EBITDA Margin 1.5%
EBITDA Margin - 3 Yr. Avg. -14.9%
Operating Margin -0.5%
Oper. Margin - 3 Yr. Avg. -16.5%
Pre-Tax Margin -1%
Pre-Tax Margin - 3 Yr. Avg. -16.9%
Net Profit Margin -1%
Net Profit Margin - 3 Yr. Avg. -16.9%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

CSII stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the CSII stock intrinsic value calculation we used $205 million for the last fiscal year's total revenue generated by Cardiovascular Systems. The default revenue input number comes from 2017 income statement of Cardiovascular Systems. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our CSII stock valuation model: a) initial revenue growth rate of 10.4% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for CSII is calculated based on our internal credit rating of Cardiovascular Systems, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Cardiovascular Systems.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of CSII stock the variable cost ratio is equal to 131.2%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for CSII stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 9.5% for Cardiovascular Systems.

Corporate tax rate of 27% is the nominal tax rate for Cardiovascular Systems. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the CSII stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for CSII are equal to 17.8%.

Life of production assets of 9.1 years is the average useful life of capital assets used in Cardiovascular Systems operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for CSII is equal to 4.4%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $118 million for Cardiovascular Systems - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 33.085 million for Cardiovascular Systems is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Cardiovascular Systems at the current share price and the inputted number of shares is $0.8 billion.

RELATED COMPANIES Price Int.Val. Rating
AVGR Avinger 0.240 0.04  str.sell
LMAT LeMaitre Vascu 31.69 30.26  sell
BSX Boston Scienti 25.77 11.44  str.sell
BCR C.R. Bard 332.80 110.81  str.sell
ABT Abbott Laborat 54.64 404.36  str.buy
ANGO AngioDynamics 17.03 7.77  str.sell

COMPANY NEWS

▶ 9 Stocks Steven Cohen Keeps Buying   [Nov-22-17 03:57PM  GuruFocus.com]
▶ Cardiovascular Systems reports 1Q loss   [Oct-25-17 05:47PM  Associated Press]
▶ Cardiovascular Systems beats 4Q profit forecasts   [12:33AM  Associated Press]
▶ Cardiovascular Systems reports 3Q loss   [May-03-17 06:01PM  Associated Press]
Financial statements of CSII
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.